Form 4 for URGN UroGen Pharma Ltd.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0001437749-24-008707 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-20 | 2024-03-18 | URGN | Schoenberg Mark | Chief Medical Off | S - Sale | $14.05 | -12.0K | 139.4K | -8% | -$168.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-03-18 | S | D | 12,000 | $14.05 | 139,437 | D | — | — | (F1) A portion of the cash receipts will be used for federal income tax purposes |